Market research
MDP.V Medexus Pharmaceuticals Inc
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 148M
- P/E ratio
- Not available
- Analyst target
- 12.5
- Dividend yield
- 0.0%
- Beta
- 1.27
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA58410Q2036
- Market cap
- 148M
- P/E ratio
- Not available
- Analyst target
- 12.5
- Dividend yield
- 0.0%
- Beta
- 1.27
About
About Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MDP.V discussion.
5 years, 5 months ago
Medexus Pharmaceuticals Inc is currently in a long term uptrend where the price is trading 14.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Medexus Pharmaceuticals Inc's total revenue rose by 94.5% to $32M since the same quarter in the previous year.
Its net income has dropped by 548.4% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 263.9% to $-4M since the same quarter in the previous year.
Based on the above factors, Medexus Pharmaceuticals Inc gets an overall score of 3/5.